These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15537834)

  • 21. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.
    Egnell AC; Eriksson C; Albertson N; Houston B; Boyer S
    J Pharmacol Exp Ther; 2003 Dec; 307(3):878-87. PubMed ID: 14557374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes.
    Zhou Q; Matsumoto S; Ding LR; Fischer NE; Inaba T
    Life Sci; 2004 Sep; 75(18):2145-55. PubMed ID: 15325841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
    Palamanda J; Feng WW; Lin CC; Nomeir AA
    Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase.
    Draper AJ; Hammock BD
    Arch Biochem Biophys; 2000 Apr; 376(1):199-205. PubMed ID: 10729206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions.
    Narimatsu S; Torigoe F; Tsuneto Y; Saito K; Hanioka N; Masuda K; Katsu T; Yamamoto S; Yamano S; Baba T; Miyata A
    Biochem Pharmacol; 2006 Dec; 72(12):1738-48. PubMed ID: 17010942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes.
    Yeung JH; Or PM
    Phytomedicine; 2011 Oct; 18(13):1170-5. PubMed ID: 21757329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of recombinant cytochrome P450 2C9 activity with diclofenac by MEKC.
    Konecný J; Jurica J; Tomandl J; Glatz Z
    Electrophoresis; 2007 Apr; 28(8):1229-34. PubMed ID: 17377945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
    Darbyshire JF; Iyer KR; Grogan J; Korzekwa KR; Trager WF
    Drug Metab Dispos; 1996 Sep; 24(9):1038-45. PubMed ID: 8886617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
    McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
    Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of the main human cytochrome P450 enzymes involved in safrole 1'-hydroxylation.
    Ueng YF; Hsieh CH; Don MJ; Chi CW; Ho LK
    Chem Res Toxicol; 2004 Aug; 17(8):1151-6. PubMed ID: 15310247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of a high-throughput radiometric cyp2c9 inhibition assay using tritiated diclofenac.
    Di Marco A; Marcucci I; Chaudhary A; Taliani M; Laufer R
    Drug Metab Dispos; 2005 Mar; 33(3):359-64. PubMed ID: 15608129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin.
    Kunze KL; Eddy AC; Gibaldi M; Trager WF
    Chirality; 1991; 3(1):24-9. PubMed ID: 2039681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine.
    Wong HL; Murphy SE; Hecht SS
    Chem Res Toxicol; 2005 Jan; 18(1):61-9. PubMed ID: 15651850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential activation of CYP2C9 variants by dapsone.
    Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
    Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
    Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
    Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
    Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
    Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
    Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides.
    Yan Z; Li J; Huebert N; Caldwell GW; Du Y; Zhong H
    Drug Metab Dispos; 2005 Jun; 33(6):706-13. PubMed ID: 15764717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.
    Hall M; Persiani S; Cheung YL; Matthews A; Cybulski ZR; Holding JD; Kapil R; D'Amato M; Makovec F; Rovati LC
    Biopharm Drug Dispos; 2004 May; 25(4):163-76. PubMed ID: 15108219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.